Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in cone photoreceptor cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 5864
Sealed predictions
- ELFN1 in dopamine neurons, braak-0.11 (p 0.787) → -0.37 (p 0.329)receipt 5871
Swarm cases
receipt 5871: ELFN1 in dopamine neurons, braak
- power
- full sample -0.28 (p 0.254, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.33 (p 0.188, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.51 (p 0.029, n 18). not the mix.
- skeptic
- leave-one-out range -0.39 to -0.19, sign flips 0; without severely affected donors -0.28 (p 0.254, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.63 (p 0.0051, n 18) vs -0.28 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ELFN1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ELFN1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.53 p 0.062 (needs p < 3.4e-4)
Receipts
loading the receipts